Navigation Links
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Date:10/19/2009

SAN DIEGO, Calif., Oct. 19, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation. Obesity 2009 is one of the largest scientific conferences in the field of obesity.

Amylin will also present new scientific findings from preclinical studies related to its clinical-stage obesity programs for pramlintide/metreleptin and davalintide, an optimized amylin analog. These findings include new insights into the synergistic weight loss observed with various dual-hormone combination regimens. Additionally, Amylin will present at the meeting's pre-conference session focused on obesity pharmacotherapy.

"The discovery of leptin and its role, along with other endocrine signals, in regulating body weight through a neurohormonal feedback system marked the beginning of a new era of obesity research," said Christian Weyer, M.D., vice president, Medical Development at Amylin Pharmaceuticals. "Amylin's unique approach to obesity drug development aims to translate this evolving science into innovative new treatment options and builds on over 20 years of experience in peptide-protein therapeutics."

Key Amylin Activities at Obesity 2009:

Saturday, October 24

  • Pharmacotherapy Update invited presentation: Christian Weyer, M.D., vice president, Medical Development will present at this pre-conference session scheduled from 1:00 - 3:45 p.m. ET.

Sunday, October 25

  • Poster 190-P: "Central Mechanisms Underlying Am
    '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Feb. 9 The rapid increase ... shadow to the CRO and CMO businesses there. However, ... and manufacturing organization that focuses on fine and pharmaceutical ... are not only low costs," said Dr. Aaron ... continues: "What makes Chemphy so attractive to our customers? ...
(Date:2/9/2010)... 9 SIRO Clinpharm, a Contract ... India , Western and Central Eastern Europe, and ... alliance with DreamCIS Inc., a leading CRO based ... DreamCIS has nearly a decade of experience in ... venture companies, medical device manufacturers, and functional food ...
(Date:2/9/2010)... , Feb. 9 Visage Imaging®, ... (ASX: PME), announces today John Danahy joins ... Services. With over 17 years in the healthcare IT ... Visage team. ,, Danahy was previously VP Sales ... and developed new business opportunities in the EMR market ...
Breaking Medicine Technology:DS Chemphy Focusing on CRO/CMO Business 2SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 2SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 3Visage Imaging Names John Danahy as General Manager North America, Sales and Services 2Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019 55412 1Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019 55412 2Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019 55412 3Randall Terry Removed By Police From Howard Dean Health Care Town Hall Meeting 55409 1Randall Terry Removed By Police From Howard Dean Health Care Town Hall Meeting 55409 2Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 1Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 2Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 3Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 4Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 5
(Date:2/9/2010)... Against Insurer-favored ,Cost Solution,: Selling Policies That Amount To ... WASHINGTON , Feb. 9 ... regulators with its premium hikes of up to 39% ... face of questions from the White House and an ... state lawmakers should act to regulate health insurance premiums ...
(Date:2/9/2010)... University,s Slone Epidemiology Center have found a direct ... type 2 diabetes in African American women. The ... Journal of Epidemiology , is the first prospective ... status and incidence of type 2 diabetes in ... , Type 2 diabetes is estimated to affect ...
(Date:2/9/2010)... 8, 2010- The research group of Dr. Franois Robert, ... Montral (IRCM), in collaboration with the team of Dr. ... Toronto) accomplished a technical breakthrough: they mapped all the ... Saccharomyces cerevisiae . The method used by the ... been published online today in the scientific journal ...
(Date:2/9/2010)... Cerebral palsy (CP) has increased in infants born prematurely ... from Loyola University Health System (LUHS). These findings were ... for Maternal-Fetal Medicine in Chicago. They also were published ... of Obstetrics & Gynecology . , Researchers reported that ... in the umbilical cord. This inflammation is more common ...
(Date:2/9/2010)... The Quantum Foundation is proud to be partners ... Palm Beach County that will help kids and their ... Foundation (RWJF) recently announced a $360,000 grant to ... foods for children and families in Lake Worth , ... rigorous selection process that drew more than 500 proposals from ...
Breaking Medicine News(10 mins):Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3Health News:Neighborhood socioeconomic status and diabetes 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 3Health News:Incidence of cerebral palsy on rise in US 2Health News:Planting Seeds to Fight Childhood Obesity 2
... 2008 A 115-year-old woman who remained mentally alert ... little or no evidence of Alzheimer,s disease, according to ... Aging ( http://neurobiologyofaging.org/ ). , The findings question the ... will inevitably develop, if people live long enough. ...
... Cancer patients who attended a specialist nurse clinic rather ... from longer, more frequent consultations and good symptom management, ... the Journal of Clinical Nursing. , And because ... 83 per cent of the consultations without referring issues ...
... and MacroArray,Technologies, LLC have entered into a development ... phone communication,technology and MacroArray,s urine diagnostic test for ... at risk of developing prostate cancer, but,unfortunately not ... simplify and expand,the use of low cost wireless ...
... June 9 ATS Medical, Inc.,(Nasdaq: ... cardiac,surgery products and services, today noted that ... experience with ATS Medical products and related,procedures ... International,Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) ...
... (NASDAQ: QLTI; TSX:,QLT) announced today that QLT USA, ... purchase agreement with Allergan Sales, LLC, a,wholly-owned subsidiary ... fully divest QLT,s,worldwide rights to Aczone(R), a prescription ... for the treatment of acne vulgaris. Under the,terms ...
... Change is Key Focus ... for AHIP 2008 Session, ... solutions for health payers, today announced that it,will host a symposium ... The Friday, June 20 breakfast meeting session,will provide health payer executives ...
Other Medicine News:Health News:World's oldest woman had normal brain 2Health News:Specialist nurses can play a key role in supporting patients having radiotherapy 2Health News:Specialist nurses can play a key role in supporting patients having radiotherapy 3Health News:Gentag, Inc. and MacroArray Technologies Join Forces 2Health News:ATS Medical Products Prominently Featured in International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Scientific Presentations 2Health News:ATS Medical Products Prominently Featured in International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Scientific Presentations 3Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 2Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 3Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 4Health News:QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million 5Health News:Adaptis Seminar to Provide Strategies for Managing Market Transformations 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: